zolmitriptan ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2869 139264-17-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zolmitriptan
  • zipton
  • zominat
  • zomigoro
  • 311C90
an antimigraine compound; a serotonin (5HT)-1D receptor agonist
  • Molecular weight: 287.36
  • Formula: C16H21N3O2
  • CLOGP: 1.29
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 57.36
  • ALOGS: -3.18
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg N
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.50 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 45 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 25, 1997 FDA IPR

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 146.22 17.44 108 7605 75172 50522239
Medication overuse headache 113.99 17.44 25 7688 610 50596801
Paranasal cyst 44.00 17.44 10 7703 288 50597123
Vascular malformation 43.83 17.44 10 7703 293 50597118
Monocyte count abnormal 43.22 17.44 9 7704 170 50597241
Infrequent bowel movements 39.02 17.44 12 7701 1126 50596285
Mastoiditis 38.15 17.44 11 7702 827 50596584
Headache 34.99 17.44 161 7552 506374 50091037
Urticaria chronic 33.87 17.44 9 7704 500 50596911
Skin candida 33.18 17.44 11 7702 1315 50596096
Lymphocyte count abnormal 31.97 17.44 9 7704 621 50596790
Dyspnoea exertional 31.60 17.44 39 7674 51194 50546217
Antibody test positive 30.70 17.44 12 7701 2299 50595112
Depression 29.97 17.44 73 7640 165350 50432061
Temperature intolerance 29.97 17.44 17 7696 7522 50589889
Vertigo 29.65 17.44 38 7675 51794 50545617
Blood thyroid stimulating hormone normal 28.63 17.44 6 7707 117 50597294
Polymenorrhagia 27.44 17.44 5 7708 45 50597366
Oral herpes 25.85 17.44 23 7690 20702 50576709
Oligohydramnios 25.68 17.44 14 7699 5736 50591675
Tuberculosis 25.41 17.44 17 7696 10066 50587345
Drug abuser 25.07 17.44 11 7702 2817 50594594
Insomnia 24.37 17.44 70 7643 174795 50422616
Vitreous detachment 22.72 17.44 9 7704 1785 50595626
Tension headache 22.21 17.44 10 7703 2721 50594690
Colitis ischaemic 21.55 17.44 15 7698 9468 50587943
Tuberculin test positive 20.74 17.44 10 7703 3176 50594235
Drug effect less than expected 20.62 17.44 6 7707 466 50596945
Otitis media 20.57 17.44 11 7702 4338 50593073
Dry mouth 20.12 17.44 33 7680 56145 50541266
Myalgia 19.52 17.44 52 7661 124267 50473144
Dizziness 18.13 17.44 102 7611 346267 50251144
Renal infarct 17.85 17.44 7 7706 1353 50596058
Broad ligament tear 17.53 17.44 3 7710 18 50597393

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy partial responder 48.90 29.70 14 894 5185 29568434
Paraesthesia 39.46 29.70 23 885 53822 29519797
Migraine 36.92 29.70 14 894 12416 29561203
Insomnia 33.41 29.70 25 883 88736 29484883
Craniosynostosis 32.65 29.70 6 902 307 29573312
Drug abuse 31.17 29.70 23 885 79860 29493759

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 161.88 18.41 95 6981 62582 64429074
Medication overuse headache 131.03 18.41 27 7049 683 64490973
Therapy partial responder 56.83 18.41 26 7050 10222 64481434
Vascular malformation 47.14 18.41 10 7066 292 64491364
Headache 46.27 18.41 145 6931 529322 63962334
Paranasal cyst 45.84 18.41 10 7066 334 64491322
Insomnia 42.43 18.41 77 6999 197759 64293897
Mastoiditis 35.80 18.41 11 7065 1434 64490222
Depression 35.12 18.41 68 7008 183223 64308433
Renal infarct 34.05 18.41 12 7064 2399 64489257
Skin candida 34.03 18.41 11 7065 1692 64489964
Burns third degree 33.52 18.41 8 7068 401 64491255
Blood thyroid stimulating hormone normal 30.50 18.41 6 7070 119 64491537
Paraesthesia 29.62 18.41 53 7023 134469 64357187
Polymenorrhagia 29.18 18.41 5 7071 44 64491612
Tuberculin test positive 24.26 18.41 10 7066 3058 64488598
Palpitations 24.07 18.41 42 7034 104446 64387210
Drug abuser 23.87 18.41 12 7064 5796 64485860
Vertigo 22.52 18.41 30 7046 58981 64432675
Meningoencephalitis bacterial 22.45 18.41 5 7071 184 64491472
Nasal oedema 22.15 18.41 7 7069 1001 64490655
Drug effect less than expected 21.91 18.41 6 7070 521 64491135
Dust allergy 21.85 18.41 7 7069 1046 64490610
Dry eye 21.82 18.41 21 7055 28998 64462658
Throat tightness 21.79 18.41 19 7057 23141 64468515
Otitis media 21.71 18.41 11 7065 5402 64486254
Colitis ischaemic 21.31 18.41 15 7061 13399 64478257
Vitreous detachment 21.22 18.41 8 7068 1936 64489720
Trigemino-cardiac reflex 21.18 18.41 5 7071 239 64491417
Disturbance in attention 20.68 18.41 24 7052 41050 64450606
Nausea 20.15 18.41 151 6925 785649 63706007
Tension headache 20.07 18.41 9 7067 3374 64488282
Temperature intolerance 19.92 18.41 12 7064 8243 64483413
Tinnitus 18.97 18.41 21 7055 34112 64457544
Vasospasm 18.50 18.41 6 7070 932 64490724

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC03 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:35941 serotonin agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Hemiplegic migraine contraindication 59292006
Cerebral arteriosclerosis contraindication 65312002
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Vascular insufficiency of intestine contraindication 82196007
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Raynaud's phenomenon contraindication 266261006
Cerebral ischemia contraindication 287731003
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.47 acidic
pKa2 8.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 7.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1E GPCR Ki 7.70 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.60 WOMBAT-PK
5-hydroxytryptamine receptor 1F GPCR Ki 7.45 WOMBAT-PK
D(2) dopamine receptor GPCR Kd 10.40 CHEMBL
D(1A) dopamine receptor GPCR Kd 9.52 CHEMBL
Adrenergic receptor alpha-2 GPCR Kd 8.15 CHEMBL

External reference:

IDSource
4021094 VUID
N0000148550 NUI
D00415 KEGG_DRUG
4021094 VANDF
C0528166 UMLSCUI
CHEBI:10124 CHEBI
CHEMBL1185 ChEMBL_ID
DB00315 DRUGBANK_ID
C089750 MESH_SUPPLEMENTAL_RECORD_UI
60857 PUBCHEM_CID
60 IUPHAR_LIGAND_ID
7408 INN_ID
2FS66TH3YW UNII
135775 RXNORM
11471 MMSL
52759 MMSL
5712 MMSL
d04253 MMSL
006460 NDDF
108406003 SNOMEDCT_US
363582006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zolmitriptan Human Prescription Drug Label 1 16571-803 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 16571-804 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 21695-955 SPRAY, METERED 5 mg NASAL NDA 28 sections
Zolmitriptan Human Prescription Drug Label 1 27241-021 TABLET 2.50 mg ORAL ANDA 24 sections
Zolmitriptan Human Prescription Drug Label 1 27241-022 TABLET 5 mg ORAL ANDA 24 sections
ZOLMITRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 31722-458 TABLET, FILM COATED 2.50 mg ORAL ANDA 19 sections
ZOLMITRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 31722-459 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 45802-711 SPRAY 5 mg NASAL ANDA 26 sections
Zolmitriptan Human Prescription Drug Label 1 46708-181 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-182 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-462 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-463 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 50742-625 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 50742-626 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 55700-943 TABLET 2.50 mg ORAL ANDA 24 sections
Zolmitriptan Human Prescription Drug Label 1 55700-944 TABLET 5 mg ORAL ANDA 24 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 59746-432 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 59746-433 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 59746-461 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 26 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 59746-462 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0101 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0102 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-671 TABLET 2.50 mg ORAL NDA 25 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-672 TABLET 5 mg ORAL NDA 25 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-681 SPRAY, METERED 5 mg NASAL NDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-682 SPRAY, METERED 2.50 mg NASAL NDA 26 sections
ZOMIG ZMT HUMAN PRESCRIPTION DRUG LABEL 1 64896-691 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL NDA 25 sections
ZOMIG ZMT HUMAN PRESCRIPTION DRUG LABEL 1 64896-692 TABLET, ORALLY DISINTEGRATING 5 mg ORAL NDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 64980-203 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 64980-204 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections